The present disclosure relates to a dermal drug delivery platform comprising: a primary wound dressing comprising three-dimensional polymer protuberances that extend upward from the dressing surface to engage the wound. The protuberances comprise at least one biocompatible and/or biodegradable polym
The present disclosure relates to a dermal drug delivery platform comprising: a primary wound dressing comprising three-dimensional polymer protuberances that extend upward from the dressing surface to engage the wound. The protuberances comprise at least one biocompatible and/or biodegradable polymer and medicinal nanoparticles. In one embodiment, the medicinal nanoparticles may be metallic and provide surface-area-enhanced galvanic action to drive medicinal ions into the wound bed. Various methods of making the disclosed dermal drug delivery platform, as well as three-dimensional methods of treating a wound using the platform are also disclosed.
대표청구항▼
1. An enhanced wound care system comprising: a primary dressing surface with numerous electrically conductive polymer protuberances fashioned thereupon;wherein the electrically conductive polymer protuberances are comprised of biocompatible and/or biodegradable polymer with numerous metallic nanopar
1. An enhanced wound care system comprising: a primary dressing surface with numerous electrically conductive polymer protuberances fashioned thereupon;wherein the electrically conductive polymer protuberances are comprised of biocompatible and/or biodegradable polymer with numerous metallic nanoparticles embedded therein;wherein the metallic nanoparticles are comprised of two or more electrochemically distinct metals;wherein the primary dressing surface is designed to electrically connect said numerous electrically conductive polymer protuberances into geometrical patterns across the wound bed;wherein the numerous electrically conductive polymer protuberances, when immersed into a wound exudate with electrolytic functionality, will establish a galvanic cell response for purposes of electrical stimulation, to accelerate the wound healing process. 2. The enhanced wound care system of claim 1, wherein the polymer protuberances have a columnar or pillar shape with a base having a longest dimension ranging from 1 μm to 1000 μm, and a cross-section shape that is round, square, rectangular, hexagonal, elliptical, completely general, or combinations thereof. 3. The enhanced wound care system of claim 1, wherein the metallic nanoparticles comprise nanoparticles of potassium. sodium, barium, calcium, manganese, chromium, cadmium, iron, nickel, tin, lead, antimony, bismuth, arsenic, mercury, silver, gold, copper, zinc, platinum, palladium, magnesium, aluminum, and/or combinations thereof. 4. The enhanced wound care system of claim 1, wherein the metallic nanoparticles are uniformly distributed within the polymer protuberances. 5. The enhanced wound care system of claim 1, wherein the metallic nanoparticles are non-uniformly distributed within the polymer protuberances. 6. The enhanced wound care system of claim 5, wherein the metallic nanoparticles have a varying concentration from the tip of the polymer protuberances to the base of the polymer protuberances. 7. The enhanced wound care system of claim 1, wherein the polymer protuberances further comprise anti-microbial, anti-fungal, anti-biotic, pain reduction, and/or growth-promoting agents. 8. The enhanced wound care system of claim 7, wherein growth-promoting agents are present and comprise Interleukins (IL-6, IL-7, IL-8), Keratinocyte growth factor (KGF) and/or Hepatocyte growth factor (HGF). 9. The enhanced wound care system of claim 1, wherein the metallic nanoparticles are spherical in shape with a diameter ranging from 2 nm to 500 nm. 10. The enhanced wound care system of claim 1, wherein the biodegradable polymer is present and comprises PLA, PGA, PEG, PLGA, PGSA, and/or combinations thereof. 11. The enhanced wound care system of claim 1, wherein the biocompatible polymer is present and comprised of PEDOT. 12. The enhanced wound care system of claim 1, wherein the molecular weight of the polymer in the polymer protuberances is chosen to optimize the controlled release rate of metallic nanoparticles into the wound. 13. The enhanced wound care system of claim 1, wherein the spacing and size of the polymer protuberances are selected so as to make the primary dressing surface Superhydrophobic. 14. The enhanced wound care system of claim 1, wherein the enhanced wound care system further comprises an outer cover and at least one layer located between the primary dressing and the outer cover. 15. The enhanced wound care system of claim 14, wherein the outer cover is comprised of a polymer, chosen from latex, mylar, polyethylene, polypropylene, nylon, rayon and/or combinations thereof. 16. The enhanced wound care system of claim 1, wherein the polymer protuberances release the metallic nanoparticles as a result of a stimulus. 17. The enhanced wound care system of claim 16, wherein said stimulus comprises a saline rinse, a change in temperature, sweat or perspiration, wound electrolytes, an electrical field, a magnetic field, or any combination of the foregoing. 18. A method of making a enhanced wound care system of claim 1 comprising: dispersing the metallic nanoparticles in the at least one biocompatible and/or biodegradable polymer; anddepositing said metallic nanoparticle containing polymer onto a primary dressing surface to form the three-dimensional polymer protuberances. 19. The method of claim 18, further comprising placing one or more secondary layers over the primary dressing on the side opposite the three-dimensional polymer protuberances. 20. The method of claim 19, further comprising placing an outer layer on top of the one or more secondary layers, such that the one or more secondary layers are located between the primary dressing and the outer layer. 21. The method of claim 18, wherein the polymer protuberances comprise multiple-species, and are formed by a method comprising: depositing a first polymer layer containing metallic nanoparticles onto the primary dressing surface;depositing a second polymer layer containing metallic nanoparticles overtop of the first polymer layer;depositing a third polymer layer containing medicinal nanoparticles overtop of the second polymer layer; andpressing a heated mold cavity with a complementary pattern of pits against the primary dressing surface and the first, second, and third polymer layers to form a pattern of multiple-specie polymer protuberances. 22. The method of claim 21, wherein the first polymer layer comprises zinc nanoparticles in PLGA; the second polymer layer comprises silver nanoparticles in PLGA; and the third polymer layer comprises as medicinal nanoparticles anti-microbial agents, anti-fungal agents, anti-biotic agents, germicidal agents, anti-bacterial agents, growth-promoting agents, pain reduction agents, and/or combinations thereof. 23. The method of claim 21, wherein the mold is made from silicon and includes a non-stick layer. 24. The method of claim 18, wherein the polymer protuberances are in the shape of a tapered cone. 25. The method of claim 18, wherein the polymer protuberances are formed by a method comprising: depositing a first polymer layer containing metallic nanoparticles onto the primary dressing surface;placing a mask over top of and proximal to the first polymer layer, wherein said mask has a pattern with openings to allow light to pass there-through;exposing the first polymer layer to UV light to cure the polymer in the mask openings only, leaving the areas not exposed to UV light uncured;removing the uncured areas of the first polymer layer thereby forming a first pattern of polymer protuberances;depositing a second polymer layer containing metallic nanoparticles onto the primary dressing surface;placing a mask over top of and proximal to the second polymer layer, wherein said mask has a pattern with openings to allow light to pass there-through;exposing the second polymer layer to UV light to cure the polymer in the mask openings only, leaving the areas not exposed to UV light uncured;removing the uncured areas of the second polymer layer thereby forming a second pattern of polymer protuberances different from the first pattern;depositing a third polymer layer containing medicinal nanoparticles onto the primary dressing surface;placing a mask over top of and proximal to the third polymer layer, wherein said mask has a pattern with openings to allow light to pass there-through;exposing the third polymer layer to UV light to cure the polymer in the mask openings only, leaving the areas not exposed to UV light uncured;removing the uncured areas of the third polymer layer thereby forming a third pattern of polymer protuberances different from both the first pattern and the second pattern. 26. The method of claim 25, wherein at least one of the first, second, or third polymer comprises PGSA. 27. The method of claim 25, wherein the first metallic nanoparticle comprises silver; the second metallic nanoparticle comprises zinc; and the third medicinal nanoparticle is selected from anti-microbial agents, anti-fungal agents, anti-biotic agents, germicidal and/or anti-bacterial agents, pain reducing agents, and/or combinations thereof. 28. A three-dimensional method of treating a wound, said method comprising: inserting the enhanced wound care system of claim 1 into a wound, wherein said polymer protuberances make direct contact with the wound exudate with electrolytic functionality. 29. The method of claim 28, wherein the biocompatible and/or biodegradable polymer dissolves in the wound and thereby releases said metallic nanoparticles into the wound. 30. The method of claim 28, wherein the metallic nanoparticles comprise potassium, sodium, barium, calcium, manganese, chromium, cadmium, iron, nickel, tin, lead, antimony, bismuth, arsenic, mercury, silver, gold, copper, zinc, platinum, palladium, magnesium, aluminum, and combinations thereof. 31. The method of claim 28, wherein the biodegradable polymer if present is selected from: PLA, PGA, PEG, PLGA and/or PGSA; and the biocompatible polymer if present is comprised of PEDOT. 32. The enhanced wound care system of claim 1, wherein each of the polymer protuberances comprises only one specie of the metallic nanoparticles made of electrochemically distinct metals.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (22)
Burrell Robert Edward (Sherwood Park CAX) Rosenfeld Aron Marcus (Kingston CAX) Smith Timothy J. N. (Kingston CAX), Actively sterile surfaces.
Chen, Mei-Chin; Chen, Dong-Hwang; Wang, Kuan-Wen; Lai, Bo-Hung, Transdermal drug delivery patch and method of controlling drug release of the same by near-IR.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.